论文信息 - Phase II study of SU5416—a small‐molecule, vascular endothelial growth factor tyrosine‐kinase receptor inhibitor—in patients with refractory myeloproliferative diseases - 字舞流文

Phase II study of SU5416—a small‐molecule, vascular endothelial growth factor tyrosine‐kinase receptor inhibitor—in patients with refractory myeloproliferative diseases

H. Kantarjian | G. Garcia-Manero | A. Stopeck | J. Cherrington | J. Karp | F. Giles | M. Albitar | M. Zangari | J. Lancet | Deborah A. Thomas | A. Hannah | M. Cooper | P. Shami | D. Thomas | L. Silverman | K. Khan | K. D. Khan | Alison T. Stopeck | Paul J. Shami